BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz EJ, Bennett M, Wang L, Harting E, Tarrant JM, McColgan BJ, Chung C, Ray AS, Subramanian GM, Myers RP, Middleton MS, Lai M, Charlton M, Harrison SA. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2018;155:1463-1473.e6. [PMID: 30059671 DOI: 10.1053/j.gastro.2018.07.027] [Cited by in Crossref: 178] [Cited by in F6Publishing: 183] [Article Influence: 35.6] [Reference Citation Analysis]
Number Citing Articles
1 Jiang M, Huang C, Wu Q, Su Y, Wang X, Xuan Z, Wang Y, Xu F, Ge C. Sini San ameliorates CCl4-induced liver fibrosis in mice by inhibiting AKT-mediated hepatocyte apoptosis. J Ethnopharmacol 2023;303:115965. [PMID: 36460296 DOI: 10.1016/j.jep.2022.115965] [Reference Citation Analysis]
2 Lawitz EJ, Bhandari BR, Ruane PJ, Kohli A, Harting E, Ding D, Chuang JC, Huss RS, Chung C, Myers RP, Loomba R. Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. Clin Gastroenterol Hepatol 2023;21:143-152.e3. [PMID: 34999207 DOI: 10.1016/j.cgh.2021.12.044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
3 Li Y, Lei R, Lei H, Xiong Q, Xie F, Yao C, Feng P. Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Eur J Gastroenterol Hepatol 2023;35:1-14. [PMID: 36468565 DOI: 10.1097/MEG.0000000000002471] [Reference Citation Analysis]
4 van Son KC, (Onno) Holleboom A, Tushuizen ME. Nonalcoholic fatty liver disease. Visceral and Ectopic Fat 2023. [DOI: 10.1016/b978-0-12-822186-0.00024-9] [Reference Citation Analysis]
5 Xu L, Yang H, Xu H, Yang R, Fen L, Jiang D, Xu L, Xing Y. Efficacy and safety of acetyl-CoA carboxylase (ACC) inhibitors in the treatment of nonalcoholic steatohepatitis (NASH): A protocol for systematic review. Medicine (Baltimore) 2022;101:e32357. [PMID: 36550852 DOI: 10.1097/MD.0000000000032357] [Reference Citation Analysis]
6 Tay PWL, Ng CH, Lin SY, Chin YH, Xiao J, Lim WH, Lim SY, Fu CE, Chan KE, Quek J, Tan DJH, Chew N, Syn N, Keitoku T, Tamaki N, Siddiqui MS, Noureddin M, Muthiah M, Huang DQ, Loomba R. Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants. Am J Gastroenterol 2022. [PMID: 36191268 DOI: 10.14309/ajg.0000000000002042] [Reference Citation Analysis]
7 Lei Y, Tang L, Chen Q, Wu L, He W, Tu D, Wang S, Chen Y, Liu S, Xie Z, Wei H, Yang S, Tang B. Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism. Nat Commun 2022;13:6862. [PMID: 36369291 DOI: 10.1038/s41467-022-34671-1] [Reference Citation Analysis]
8 Yeudall S, Upchurch CM, Seegren PV, Pavelec CM, Greulich J, Lemke MC, Harris TE, Desai BN, Hoehn KL, Leitinger N. Macrophage acetyl-CoA carboxylase regulates acute inflammation through control of glucose and lipid metabolism. Sci Adv 2022;8:eabq1984. [PMID: 36417534 DOI: 10.1126/sciadv.abq1984] [Reference Citation Analysis]
9 Zhang D, Zhang Y, Sun B. The Molecular Mechanisms of Liver Fibrosis and Its Potential Therapy in Application. IJMS 2022;23:12572. [DOI: 10.3390/ijms232012572] [Reference Citation Analysis]
10 Kayampilly P, Roeser N, Rajendiran TM, Pennathur S, Afshinnia F. Acetyl Co-A Carboxylase Inhibition Halts Hyperglycemia Induced Upregulation of De Novo Lipogenesis in Podocytes and Proximal Tubular Cells. Metabolites 2022;12:940. [DOI: 10.3390/metabo12100940] [Reference Citation Analysis]
11 Suri J, Borja S, Lim JK. Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis. World J Gastroenterol 2022; 28(35): 5129-5140 [DOI: 10.3748/wjg.v28.i35.5129] [Reference Citation Analysis]
12 O'Farrell M, Duke G, Crowley R, Buckley D, Martins EB, Bhattacharya D, Friedman SL, Kemble G. FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models. Sci Rep 2022;12:15661. [PMID: 36123383 DOI: 10.1038/s41598-022-19459-z] [Reference Citation Analysis]
13 Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu Y, Billin AN, Damgaard LH, Buchholtz K, Kjær MS, Balendran C, Myers RP, Loomba R, Noureddin M. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. J Hepatol 2022;77:607-18. [PMID: 35439567 DOI: 10.1016/j.jhep.2022.04.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
14 Yang L, Li JZ, Li MR. Progress in research of lipogenesis inhibitors for treatment of nonalcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2022; 30(16): 735-742 [DOI: 10.11569/wcjd.v30.i16.735] [Reference Citation Analysis]
15 Arredouani A. Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment. Lifestyle-Related Diseases and Metabolic Syndrome [Working Title] 2022. [DOI: 10.5772/intechopen.106445] [Reference Citation Analysis]
16 Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther 2022;7:287. [PMID: 35963848 DOI: 10.1038/s41392-022-01119-3] [Reference Citation Analysis]
17 Hyrina A, Burdette D, Song Z, Ramirez R, Okesli-armlovich A, Vijayakumar A, Bates J, Trevaskis JL, Fletcher SP, Lee WA, Holdorf MM. Targeting lipid biosynthesis pathways for hepatitis B virus cure. PLoS ONE 2022;17:e0270273. [DOI: 10.1371/journal.pone.0270273] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Wang Z, Ye M, Zhang XJ, Zhang P, Cai J, Li H, She ZG. Impact of NAFLD and its pharmacotherapy on lipid profile and CVD. Atherosclerosis 2022;355:30-44. [PMID: 35872444 DOI: 10.1016/j.atherosclerosis.2022.07.010] [Reference Citation Analysis]
19 Makri ES, Makri E, Polyzos SA. Combination Therapies for Nonalcoholic Fatty Liver Disease. JPM 2022;12:1166. [DOI: 10.3390/jpm12071166] [Reference Citation Analysis]
20 An Q, Lin R, Wang D, Wang C. Emerging roles of fatty acid metabolism in cancer and their targeted drug development. Eur J Med Chem 2022;240:114613. [PMID: 35853429 DOI: 10.1016/j.ejmech.2022.114613] [Reference Citation Analysis]
21 Iwaki M, Kessoku T, Tanaka K, Ozaki A, Kasai Y, Yamamoto A, Takahashi K, Kobayashi T, Nogami A, Honda Y, Ogawa Y, Imajo K, Yoneda M, Kobayashi N, Saito S, Nakajima A. Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study. BMJ Open 2022;12:e060335. [PMID: 35820743 DOI: 10.1136/bmjopen-2021-060335] [Reference Citation Analysis]
22 Fondevila MF, Fernandez U, Heras V, Parracho T, Gonzalez-Rellan MJ, Novoa E, Porteiro B, Alonso C, Mayo R, da Silva Lima N, Iglesias C, Filliol AA, Senra A, Delgado TC, Woodhoo A, Herrero L, Serra D, Prevot V, Schwaninger M, López M, Dieguez C, Millet O, Mato JM, Cubero FJ, Varela-Rey M, Iruzubieta P, Crespo J, Martinez-Chantar ML, Schwabe RF, Nogueiras R. Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis. J Hepatol 2022;77:15-28. [PMID: 35167910 DOI: 10.1016/j.jhep.2022.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Leslie J, Geh D, Elsharkawy AM, Mann DA, Vacca M. Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions. J Hepatol 2022;77:219-36. [PMID: 35157957 DOI: 10.1016/j.jhep.2022.01.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
24 Vijayakumar A, Okesli-Armlovich A, Wang T, Olson I, Seung M, Kusam S, Hollenback D, Mahadevan S, Marchand B, Toteva M, Breckenridge DG, Trevaskis JL, Bates J. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. Hepatol Commun 2022. [PMID: 35735253 DOI: 10.1002/hep4.2011] [Reference Citation Analysis]
25 Assante G, Chandrasekaran S, Ng S, Tourna A, Chung CH, Isse KA, Banks JL, Soffientini U, Filippi C, Dhawan A, Liu M, Rozen SG, Hoare M, Campbell P, Ballard JWO, Turner N, Morris MJ, Chokshi S, Youngson NA. Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease. Genome Med 2022;14:67. [PMID: 35739588 DOI: 10.1186/s13073-022-01071-5] [Reference Citation Analysis]
26 Harrison SA, Manghi FP, Smith WB, Alpenidze D, Aizenberg D, Klarenbeek N, Chen CY, Zuckerman E, Ravussin E, Charatcharoenwitthaya P, Cheng PN, Katchman H, Klein S, Ben-Ari Z, Mendonza AE, Zhang Y, Martic M, Ma S, Kao S, Tanner S, Pachori A, Badman MK, He Y, Ukomadu C, Sicard E. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. Nat Med 2022. [PMID: 35725922 DOI: 10.1038/s41591-022-01861-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Ratziu V, Francque S, Sanyal A. Breakthroughs in therapies for NASH and remaining challenges. J Hepatol 2022;76:1263-78. [PMID: 35589249 DOI: 10.1016/j.jhep.2022.04.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
28 Rowe IA, Wong VW, Loomba R. Treatment Candidacy for Pharmacologic Therapies for NASH. Clin Gastroenterol Hepatol 2022;20:1209-17. [PMID: 33711479 DOI: 10.1016/j.cgh.2021.03.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
29 Yu HX, Feng Z, Lin W, Yang K, Liu RQ, Li JQ, Liu XY, Pei M, Yang HT. Ongoing Clinical Trials in Aging-Related Tissue Fibrosis and New Findings Related to AhR Pathways. Aging Dis 2022;13:732-52. [PMID: 35656117 DOI: 10.14336/AD.2021.1105] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. Curr Atheroscler Rep 2022. [PMID: 35507280 DOI: 10.1007/s11883-022-01027-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
31 Marjot T, Ray DW, Tomlinson JW. Is it time for chronopharmacology in NASH? J Hepatol 2022;76:1215-24. [PMID: 35066087 DOI: 10.1016/j.jhep.2021.12.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
32 Yang YY, Xie L, Zhang NP, Zhou D, Liu TT, Wu J. Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022;43:1180-90. [PMID: 35190696 DOI: 10.1038/s41401-022-00860-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
33 Neri CR, Scapaticci S, Chiarelli F, Giannini C. Liver Steatosis: A Marker of Metabolic Risk in Children. Int J Mol Sci 2022;23:4822. [PMID: 35563210 DOI: 10.3390/ijms23094822] [Reference Citation Analysis]
34 Ryder TF, Bergman A, King-Ahmad A, Amin NB, Lall MS, Ballard TE, Kalgutkar AS. Pharmacokinetics, Mass Balance, Metabolism, and Excretion of the Liver-Targeted Acetyl-CoA Carboxylase Inhibitor PF-05221304 (Clesacostat) in Humans. Xenobiotica 2022;:1-45. [PMID: 35382680 DOI: 10.1080/00498254.2022.2062487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Amin NB, Darekar A, Anstee QM, Wong VW, Tacke F, Vourvahis M, Lee DS, Charlton M, Alkhouri N, Nakajima A, Yunis C. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study. BMJ Open 2022;12:e056159. [PMID: 35354614 DOI: 10.1136/bmjopen-2021-056159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Kemas AM, Youhanna S, Lauschke VM. Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development. Expert Review of Precision Medicine and Drug Development 2022;7:39-49. [DOI: 10.1080/23808993.2022.2053285] [Reference Citation Analysis]
37 Li H, Liu NN, Li JR, Dong B, Wang MX, Tan JL, Wang XK, Jiang J, Lei L, Li HY, Sun H, Jiang JD, Peng ZG. Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease. Front Pharmacol 2022;13:843872. [PMID: 35250593 DOI: 10.3389/fphar.2022.843872] [Reference Citation Analysis]
38 Cunha GM, Delgado T, Middleton MS, Liew S, Henderson WC, Batakis D, Wang K, Loomba R, Huss RS, Myers RP, Sirlin CB, Fowler KJ, Hasenstab KA. Automated CNN-Based Analysis Versus Manual Analysis for MR Elastography in Nonalcoholic Fatty Liver Disease: Inter-method Agreement and Fibrosis Stage Discriminative Performance. AJR Am J Roentgenol 2022. [PMID: 35107306 DOI: 10.2214/AJR.21.27135] [Reference Citation Analysis]
39 Bian H, Liu YM, Chen ZN. New avenues for NASH therapy by targeting ACC. Cell Metab 2022;34:191-3. [PMID: 35108509 DOI: 10.1016/j.cmet.2022.01.001] [Reference Citation Analysis]
40 Fidelito G, Watt MJ, Taylor RA. Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality? Front Oncol 2022;11:778761. [DOI: 10.3389/fonc.2021.778761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Batchuluun B, Pinkosky SL, Steinberg GR. Lipogenesis inhibitors: therapeutic opportunities and challenges. Nat Rev Drug Discov 2022. [PMID: 35031766 DOI: 10.1038/s41573-021-00367-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
42 Garbuzenko DV. Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2022;31:16-24. [DOI: 10.22416/1382-4376-2021-31-5-16-24] [Reference Citation Analysis]
43 F. Lange N, Dufour J. Spezifische Therapie – neue Medikamente. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_21] [Reference Citation Analysis]
44 Georgescu CE. Polycystic ovary syndrome and nonalcoholic fatty liver disease. Polycystic Ovary Syndrome 2022. [DOI: 10.1016/b978-0-12-823045-9.00007-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Lee YA, Friedman SL. Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies. J Intern Med 2022;291:11-31. [PMID: 34564899 DOI: 10.1111/joim.13380] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
46 Su M, Cao D, Wang Z, Duan Y, Huang Y. Fatty Acid Synthase Inhibitor Platensimycin Intervenes the Development of Nonalcoholic Fatty Liver Disease in a Mouse Model. Biomedicines 2021;10:5. [DOI: 10.3390/biomedicines10010005] [Reference Citation Analysis]
47 Zhang XJ, Ji YX, Cheng X, Cheng Y, Yang H, Wang J, Zhao LP, Huang YP, Sun D, Xiang H, Shen LJ, Li PL, Ma JP, Tian RF, Yang J, Yao X, Xu H, Liao R, Xiao L, Zhang P, Zhang X, Zhao GN, Wang X, Hu ML, Tian S, Wan J, Cai J, Ma X, Xu Q, Wang Y, Touyz RM, Liu PP, Loomba R, She ZG, Li H. A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques. Sci Transl Med 2021;13:eabg8116. [PMID: 34910548 DOI: 10.1126/scitranslmed.abg8116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
48 Zhang XJ, She ZG, Wang J, Sun D, Shen LJ, Xiang H, Cheng X, Ji YX, Huang YP, Li PL, Yang X, Cheng Y, Ma JP, Wang HP, Hu Y, Hu F, Tian S, Tian H, Zhang P, Zhao GN, Wang L, Hu ML, Yang Q, Zhu LH, Cai J, Yang J, Zhang X, Ma X, Xu Q, Touyz RM, Liu PP, Loomba R, Wang Y, Li H. Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis. Sci Transl Med 2021;13:eabg8117. [PMID: 34910546 DOI: 10.1126/scitranslmed.abg8117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
49 Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T, Filipovic N, Al Kiswani J, Djokovic A, Kapor S, Kapor S, Bukumiric Z, Starcevic A. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:13219. [PMID: 34948020 DOI: 10.3390/ijms222413219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
50 Zhang XJ, Cai J, Li H. Targeting ACC for NASH resolution. Trends Mol Med 2022;28:5-7. [PMID: 34844875 DOI: 10.1016/j.molmed.2021.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
51 Ströbel S, Kostadinova R, Fiaschetti-Egli K, Rupp J, Bieri M, Pawlowska A, Busler D, Hofstetter T, Sanchez K, Grepper S, Thoma E. A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates. Sci Rep 2021;11:22765. [PMID: 34815444 DOI: 10.1038/s41598-021-01951-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
52 Satiya J, Snyder HS, Singh SP, Satapathy SK. Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. Transl Gastroenterol Hepatol 2021;6:60. [PMID: 34805582 DOI: 10.21037/tgh-20-247] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
53 Yenilmez B, Wetoska N, Kelly M, Echeverria D, Min K, Lifshitz L, Alterman JF, Hassler MR, Hildebrand S, DiMarzio C, McHugh N, Vangjeli L, Sousa J, Pan M, Han X, Brehm MA, Khvorova A, Czech MP. An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis. Mol Ther 2021:S1525-0016(21)00578-5. [PMID: 34774753 DOI: 10.1016/j.ymthe.2021.11.007] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F, Li H. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2021;8:761538. [PMID: 34746195 DOI: 10.3389/fmed.2021.761538] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
55 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Cited by in Crossref: 42] [Cited by in F6Publishing: 56] [Article Influence: 21.0] [Reference Citation Analysis]
56 Stine JG, Munaganuru N, Barnard A, Wang JL, Kaulback K, Argo CK, Singh S, Fowler KJ, Sirlin CB, Loomba R. Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2021;19:2274-2283.e5. [PMID: 32882428 DOI: 10.1016/j.cgh.2020.08.061] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
57 Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O'Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble G. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology 2021;161:1475-86. [PMID: 34310978 DOI: 10.1053/j.gastro.2021.07.025] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 16.0] [Reference Citation Analysis]
58 Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M, Vogl T, Loomba R, Plum-Mörschel L. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2021;54:1150-61. [PMID: 34570916 DOI: 10.1111/apt.16608] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
59 Nakajima A, Eguchi Y, Yoneda M, Imajo K, Tamaki N, Suganami H, Nojima T, Tanigawa R, Iizuka M, Iida Y, Loomba R. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2021;54:1263-77. [PMID: 34528723 DOI: 10.1111/apt.16596] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 16.5] [Reference Citation Analysis]
60 Yki-Järvinen H, Luukkonen PK, Hodson L, Moore JB. Dietary carbohydrates and fats in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2021;18:770-86. [PMID: 34257427 DOI: 10.1038/s41575-021-00472-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 24.5] [Reference Citation Analysis]
61 Parlati L, Régnier M, Guillou H, Postic C. New targets for NAFLD. JHEP Rep 2021;3:100346. [PMID: 34667947 DOI: 10.1016/j.jhepr.2021.100346] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 10.5] [Reference Citation Analysis]
62 Neokosmidis G, Cholongitas E, Tziomalos K. Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit? World J Gastroenterol 2021; 27(39): 6522-6526 [PMID: 34754150 DOI: 10.3748/wjg.v27.i39.6522] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
63 Calle RA, Amin NB, Carvajal-Gonzalez S, Ross TT, Bergman A, Aggarwal S, Crowley C, Rinaldi A, Mancuso J, Aggarwal N, Somayaji V, Inglot M, Tuthill TA, Kou K, Boucher M, Tesz G, Dullea R, Bence KK, Kim AM, Pfefferkorn JA, Esler WP. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nat Med 2021;27:1836-48. [PMID: 34635855 DOI: 10.1038/s41591-021-01489-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 14.5] [Reference Citation Analysis]
64 Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, Arrese M, Fracanzani AL, Ben Bashat D, Lackner K, Gorfine T, Kadosh S, Oren R, Halperin M, Hayardeny L, Loomba R, Friedman S, Sanyal AJ; ARREST investigator study group. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med 2021;27:1825-35. [PMID: 34621052 DOI: 10.1038/s41591-021-01495-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
65 Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y, Yao Y, Ye T. Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy. Front Cell Dev Biol 2021;9:730176. [PMID: 34621747 DOI: 10.3389/fcell.2021.730176] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 16.5] [Reference Citation Analysis]
66 Wong GL, Wong VW. Targeting an energy sensor to prevent energy excess in the liver. Lancet Gastroenterol Hepatol 2021;6:876-7. [PMID: 34560016 DOI: 10.1016/S2468-1253(21)00307-1] [Reference Citation Analysis]
67 Li Y, Sun Y, Zhang X, Wang X, Yang P, Guan X, Wang Y, Zhou X, Hu P, Jiang T, Xu Z. Relationship between amniotic fluid metabolic profile with fetal gender, maternal age, and gestational week. BMC Pregnancy Childbirth 2021;21:638. [PMID: 34537001 DOI: 10.1186/s12884-021-04116-6] [Reference Citation Analysis]
68 Lu Q, Tian X, Wu H, Huang J, Li M, Mei Z, Zhou L, Xie H, Zheng S. Metabolic Changes of Hepatocytes in NAFLD. Front Physiol 2021;12:710420. [PMID: 34526911 DOI: 10.3389/fphys.2021.710420] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
69 Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18:599-612. [PMID: 33972770 DOI: 10.1038/s41575-021-00448-y] [Cited by in Crossref: 129] [Cited by in F6Publishing: 113] [Article Influence: 64.5] [Reference Citation Analysis]
70 Brown E, Hydes T, Hamid A, Cuthbertson DJ. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Clin Ther 2021;43:1476-504. [PMID: 34446271 DOI: 10.1016/j.clinthera.2021.07.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
71 Liefwalker DF, Ryan M, Wang Z, Pathak KV, Plaisier S, Shah V, Babra B, Dewson GS, Lai IK, Mosley AR, Fueger PT, Casey SC, Jiang L, Pirrotte P, Swaminathan S, Sears RC. Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies. Cancer Metab 2021;9:31. [PMID: 34399819 DOI: 10.1186/s40170-021-00263-8] [Reference Citation Analysis]
72 Brandenburg J, Marwitz S, Tazoll SC, Waldow F, Kalsdorf B, Vierbuchen T, Scholzen T, Gross A, Goldenbaum S, Hölscher A, Hein M, Linnemann L, Reimann M, Kispert A, Leitges M, Rupp J, Lange C, Niemann S, Behrends J, Goldmann T, Heine H, Schaible UE, Hölscher C, Schwudke D, Reiling N. WNT6/ACC2-induced storage of triacylglycerols in macrophages is exploited by Mycobacterium tuberculosis. J Clin Invest 2021;131:141833. [PMID: 34255743 DOI: 10.1172/JCI141833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
73 Hydes T, Brown E, Hamid A, Bateman AC, Cuthbertson DJ. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications. Clin Ther 2021:S0149-2918(21)00256-3. [PMID: 34400007 DOI: 10.1016/j.clinthera.2021.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
74 Caputo M, Kurhe Y, Kumari S, Cansby E, Amrutkar M, Scandalis E, Booten SL, Ståhlman M, Borén J, Marschall HU, Aghajan M, Mahlapuu M. Silencing of STE20-type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet-induced nonalcoholic fatty liver disease. FASEB J 2021;35:e21567. [PMID: 33891332 DOI: 10.1096/fj.202002671RR] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
75 Assante G, Chandrasekaran S, Ng S, Tourna A, Chung CH, Isse KA, Filippi C, Dhawan A, Liu M, Rozen SG, Hoare M, Campbell P, Ballard JWO, Turner N, Morris MJ, Chokshi S, Youngson NA. Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease.. [DOI: 10.1101/2021.07.22.453333] [Reference Citation Analysis]
76 von Loeffelholz C, Coldewey SM, Birkenfeld AL. A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies. Cells 2021;10:1822. [PMID: 34359991 DOI: 10.3390/cells10071822] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
77 Zhang C, Yang M. Current Options and Future Directions for NAFLD and NASH Treatment. Int J Mol Sci 2021;22:7571. [PMID: 34299189 DOI: 10.3390/ijms22147571] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
78 Orabi D, Berger NA, Brown JM. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers (Basel) 2021;13:3473. [PMID: 34298687 DOI: 10.3390/cancers13143473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
79 Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020;41. [PMID: 31629366 DOI: 10.1210/endrev/bnz009] [Cited by in Crossref: 70] [Cited by in F6Publishing: 80] [Article Influence: 35.0] [Reference Citation Analysis]
80 Hliwa A, Ramos-Molina B, Laski D, Mika A, Sledzinski T. The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update. Int J Mol Sci 2021;22:6900. [PMID: 34199035 DOI: 10.3390/ijms22136900] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
81 Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021;17:484-95. [PMID: 34131333 DOI: 10.1038/s41574-021-00507-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 23.5] [Reference Citation Analysis]
82 Finotti M, Romano M, Auricchio P, Scopelliti M, Brizzolari M, Grossi U, Piccino M, Benvenuti S, Morana G, Cillo U, Zanus G. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. J Pers Med 2021;11:499. [PMID: 34199535 DOI: 10.3390/jpm11060499] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
83 Gilgenkrantz H, Mallat A, Moreau R, Lotersztajn S. Targeting cell-intrinsic metabolism for antifibrotic therapy. J Hepatol 2021;74:1442-54. [PMID: 33631228 DOI: 10.1016/j.jhep.2021.02.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
84 Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2021;18:373-92. [PMID: 33568794 DOI: 10.1038/s41575-020-00408-y] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 46.0] [Reference Citation Analysis]
85 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
86 Ortiz V, Ellenberg SS, Weinberg EM. Blinding in Clinical Trials for Chronic Liver Diseases. Semin Liver Dis 2021;41:163-71. [PMID: 33957695 DOI: 10.1055/s-0041-1723753] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Fallowfield JA, Jimenez-Ramos M, Robertson A. Emerging synthetic drugs for the treatment of liver cirrhosis. Expert Opin Emerg Drugs 2021;26:149-63. [PMID: 33856246 DOI: 10.1080/14728214.2021.1918099] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
88 Gastaldelli A, Stefan N, Häring HU. Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia 2021;64:1461-79. [PMID: 33877366 DOI: 10.1007/s00125-021-05442-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
89 Tacke F, Weiskirchen R. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Ann Transl Med 2021;9:729. [PMID: 33987427 DOI: 10.21037/atm-20-4354] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 14.0] [Reference Citation Analysis]
90 Hardesty JE, Wahlang B, Prough RA, Head KZ, Wilkey D, Merchant M, Shi H, Jin J, Cave MC. Effect of Epidermal Growth Factor Treatment and Polychlorinated Biphenyl Exposure in a Dietary-Exposure Mouse Model of Steatohepatitis. Environ Health Perspect 2021;129:37010. [PMID: 33788613 DOI: 10.1289/EHP8222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
91 Al Attar A, Antaramian A, Noureddin M. Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. Expert Rev Clin Pharmacol 2021;14:457-64. [PMID: 33612037 DOI: 10.1080/17512433.2021.1894127] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
92 Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 2021;23:1069-83. [PMID: 33464677 DOI: 10.1111/dom.14322] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 24.0] [Reference Citation Analysis]
93 Xia M, Chandrasekaran P, Rong S, Fu X, Mitsche MA. Hepatic deletion of Mboat7 (LPIAT1) causes activation of SREBP-1c and fatty liver. J Lipid Res 2021;62:100031. [PMID: 32859645 DOI: 10.1194/jlr.RA120000856] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
94 Fondevila MF, Fernandez U, Gonzalez-Rellan MJ, Da Silva Lima N, Buque X, Gonzalez-Rodriguez A, Alonso C, Iruarrizaga-Lejarreta M, Delgado TC, Varela-Rey M, Senra A, Garcia-Outeiral V, Novoa E, Iglesias C, Porteiro B, Beiroa D, Folgueira C, Tojo M, Torres JL, Hernández-Cosido L, Blanco Ó, Arab JP, Barrera F, Guallar D, Fidalgo M, López M, Dieguez C, Marcos M, Martinez-Chantar ML, Arrese M, Garcia-Monzon C, Mato JM, Aspichueta P, Nogueiras R. The L-α-Lysophosphatidylinositol/G Protein-Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis. Hepatology 2021;73:606-24. [PMID: 32329085 DOI: 10.1002/hep.31290] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
95 Shen B, Lu LG. Efficacy and safety of drugs for nonalcoholic steatohepatitis. J Dig Dis 2021;22:72-82. [PMID: 33385317 DOI: 10.1111/1751-2980.12967] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
96 Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G, Bhandari BR, Gunn N, Caldwell SH, Goodman Z, Wapinski I, Resnick M, Beck AH, Ding D, Jia C, Chuang JC, Huss RS, Chung C, Subramanian GM, Myers RP, Patel K, Borg BB, Ghalib R, Kabler H, Poulos J, Younes Z, Elkhashab M, Hassanein T, Iyer R, Ruane P, Shiffman ML, Strasser S, Wong VW, Alkhouri N; ATLAS Investigators. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. Hepatology 2021;73:625-43. [PMID: 33169409 DOI: 10.1002/hep.31622] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 41.0] [Reference Citation Analysis]
97 Patikorn C, Veettil SK, Phisalprapa P, Pham T, Kowdley KV, Chaiyakunapruk N. Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. Ann Hepatol 2021;24:100315. [PMID: 33515800 DOI: 10.1016/j.aohep.2021.100315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Palmieri B, Corazzari V, Panariello Brasile DG, Sangiovanni V, VadalÀ M. Hepatic steatosis integrated approach: nutritional guidelines and joined nutraceutical administration. Minerva Gastroenterol Dietol 2020;66:307-20. [PMID: 33443240 DOI: 10.23736/S1121-421X.20.02738-5] [Reference Citation Analysis]
99 Asgharpour A, Dinani A, Friedman SL. Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry. Transl Gastroenterol Hepatol 2021;6:5. [PMID: 33409399 DOI: 10.21037/tgh.2020.01.04] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
100 Sukjoi W, Ngamkham J, Attwood PV, Jitrapakdee S. Targeting Cancer Metabolism and Current Anti-Cancer Drugs. Adv Exp Med Biol 2021;1286:15-48. [PMID: 33725343 DOI: 10.1007/978-3-030-55035-6_2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
101 França M, Louro JM. Liver Steatosis and NAFLD. Imaging of the Liver and Intra-hepatic Biliary Tract 2021. [DOI: 10.1007/978-3-030-38983-3_13] [Reference Citation Analysis]
102 Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease. Mol Metab 2021;50:101143. [PMID: 33346069 DOI: 10.1016/j.molmet.2020.101143] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 13.3] [Reference Citation Analysis]
103 Beysen C, Schroeder P, Wu E, Brevard J, Ribadeneira M, Lu W, Dole K, O'Reilly T, Morrow L, Hompesch M, Hellerstein MK, Li K, Johansson L, Kelly PF. Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials. Diabetes Obes Metab 2021;23:700-10. [PMID: 33289350 DOI: 10.1111/dom.14272] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
104 Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol 2021;18:73-91. [PMID: 33268887 DOI: 10.1038/s41423-020-00579-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]
105 Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 2021;50:101122. [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 12.7] [Reference Citation Analysis]
106 Xu H, Zhao Q, Song N, Yan Z, Lin R, Wu S, Jiang L, Hong S, Xie J, Zhou H, Wang R, Jiang X. AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis. Nat Commun 2020;11:5807. [PMID: 33199780 DOI: 10.1038/s41467-020-19668-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
107 Tang J, Xiong K, Zhang T, Han Han. Application of Metabolomics in Diagnosis and Treatment of Chronic Liver Diseases. Crit Rev Anal Chem 2020;:1-11. [PMID: 33146026 DOI: 10.1080/10408347.2020.1842172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
108 Mukherjee S. Advances in the treatment of nonalcoholic steatohepatitis. World J Pharmacol 2020; 9(1): 1-12 [DOI: 10.5497/wjp.v9.i1.1] [Reference Citation Analysis]
109 Fernández LP, Gómez de Cedrón M, Ramírez de Molina A. Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment. Front Oncol 2020;10:577420. [PMID: 33194695 DOI: 10.3389/fonc.2020.577420] [Cited by in Crossref: 51] [Cited by in F6Publishing: 59] [Article Influence: 17.0] [Reference Citation Analysis]
110 Drenth JP, Schattenberg JM. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. Expert Opinion on Investigational Drugs 2020;29:1365-75. [DOI: 10.1080/13543784.2020.1839888] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
111 Jeong SW. Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. Diabetes Metab J. 2020;44:640-657. [PMID: 33115209 DOI: 10.4093/dmj.2020.0115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
112 Uo T, Sprenger CC, Plymate SR. Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer. Front Oncol 2020;10:580617. [PMID: 33163409 DOI: 10.3389/fonc.2020.580617] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
113 Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab 2020;42:101092. [PMID: 33010471 DOI: 10.1016/j.molmet.2020.101092] [Cited by in Crossref: 60] [Cited by in F6Publishing: 76] [Article Influence: 20.0] [Reference Citation Analysis]
114 Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut 2020;69:1877-84. [PMID: 32381514 DOI: 10.1136/gutjnl-2019-319104] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 26.3] [Reference Citation Analysis]
115 Bates J, Vijayakumar A, Ghoshal S, Marchand B, Yi S, Kornyeyev D, Zagorska A, Hollenback D, Walker K, Liu K, Pendem S, Newstrom D, Brockett R, Mikaelian I, Kusam S, Ramirez R, Lopez D, Li L, Fuchs BC, Breckenridge DG. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. J Hepatol 2020;73:896-905. [PMID: 32376414 DOI: 10.1016/j.jhep.2020.04.037] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 19.3] [Reference Citation Analysis]
116 Polyzos SA, Kang ES, Boutari C, Rhee E, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 2020;111:154203. [DOI: 10.1016/j.metabol.2020.154203] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 21.7] [Reference Citation Analysis]
117 Huard K, Smith AC, Cappon G, Dow RL, Edmonds DJ, El-Kattan A, Esler WP, Fernando DP, Griffith DA, Kalgutkar AS, Ross TT, Bagley SW, Beebe D, Bi YA, Cabral S, Crowley C, Doran SD, Dowling MS, Liras S, Mascitti V, Niosi M, Pfefferkorn JA, Polivkova J, Préville C, Price DA, Shavnya A, Shirai N, Smith AH, Southers JR, Tess DA, Thuma BA, Varma MV, Yang X. Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting. J Med Chem 2020;63:10879-96. [PMID: 32809824 DOI: 10.1021/acs.jmedchem.0c00640] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
118 Sunami Y. NASH, Fibrosis and Hepatocellular Carcinoma: Lipid Synthesis and Glutamine/Acetate Signaling. Int J Mol Sci 2020;21:E6799. [PMID: 32947972 DOI: 10.3390/ijms21186799] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
119 Kelly KL, Reagan WJ, Sonnenberg GE, Clasquin M, Hales K, Asano S, Amor PA, Carvajal-gonzalez S, Shirai N, Matthews MD, Li KW, Hellerstein MK, Vera NB, Ross TT, Cappon G, Bergman A, Buckeridge C, Sun Z, Qejvanaj EZ, Schmahai T, Beebe D, Pfefferkorn JA, Esler WP. De novo lipogenesis is essential for platelet production in humans. Nat Metab 2020;2:1163-78. [DOI: 10.1038/s42255-020-00272-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
120 Aggarwal P, Singh T, Alkhouri N. Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root. Curr Hepatology Rep 2020;19:302-314. [DOI: 10.1007/s11901-020-00533-x] [Reference Citation Analysis]
121 Chai C, Cox B, Yaish D, Gross D, Rosenberg N, Amblard F, Shemuelian Z, Gefen M, Korach A, Tirosh O, Lanton T, Link H, Tam J, Permyakova A, Ozhan G, Citrin J, Liao H, Tannous M, Hahn M, Axelrod J, Arretxe E, Alonso C, Martinez-Arranz I, Betés PO, Safadi R, Salhab A, Amer J, Tber Z, Mengshetti S, Giladi H, Schinazi RF, Galun E. Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122. Gastroenterology 2020;159:999-1014.e9. [PMID: 32450149 DOI: 10.1053/j.gastro.2020.05.056] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
122 Attia SL, Softic S, Mouzaki M. Evolving Role for Pharmacotherapy in NAFLD/NASH. Clin Transl Sci 2021;14:11-9. [PMID: 32583961 DOI: 10.1111/cts.12839] [Cited by in Crossref: 34] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
123 Connelly MA, Velez Rivera J, Guyton JR, Siddiqui MS, Sanyal AJ. Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2020;52:619-36. [PMID: 32638417 DOI: 10.1111/apt.15935] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
124 Lambrecht J, Tacke F. Acetyl-CoA Carboxylase Inhibition as a Therapeutic Tool in the Battle Against NASH: Hitting More Than Just One Mechanism? Cell Mol Gastroenterol Hepatol 2020;10:859-61. [PMID: 32730829 DOI: 10.1016/j.jcmgh.2020.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
125 Ampuero J, Romero-Gomez M. Stratification of patients in NASH clinical trials: A pitfall for trial success. JHEP Rep 2020;2:100148. [PMID: 32954243 DOI: 10.1016/j.jhepr.2020.100148] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
126 Johansson KS, Sonne DP, Knop FK, Christensen MB. What is on the horizon for type 2 diabetes pharmacotherapy? – An overview of the antidiabetic drug development pipeline. Expert Opinion on Drug Discovery 2020;15:1253-65. [DOI: 10.1080/17460441.2020.1791078] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
127 Syed-Abdul MM, Parks EJ, Gaballah AH, Bingham K, Hammoud GM, Kemble G, Buckley D, McCulloch W, Manrique-Acevedo C. Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology 2020;72:103-18. [PMID: 31630414 DOI: 10.1002/hep.31000] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 15.7] [Reference Citation Analysis]
128 Wang D, Hiebl V, Schachner D, Ladurner A, Heiss EH, Atanasov AG, Dirsch VM. Soraphen A enhances macrophage cholesterol efflux via indirect LXR activation and ABCA1 upregulation. Biochemical Pharmacology 2020;177:114022. [DOI: 10.1016/j.bcp.2020.114022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
129 Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, Kayali Z, Wong VW, Greenbloom S, Jayakumar S, Shiffman ML, Freilich B, Lawitz EJ, Gane EJ, Harting E, Xu J, Billin AN, Chung C, Djedjos CS, Subramanian GM, Myers RP, Middleton MS, Rinella M, Noureddin M. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. Hepatology 2020;72:58-71. [PMID: 32115759 DOI: 10.1002/hep.31205] [Cited by in Crossref: 139] [Cited by in F6Publishing: 128] [Article Influence: 46.3] [Reference Citation Analysis]
130 Lambrecht J, van Grunsven LA, Tacke F. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. Expert Opin Pharmacother 2020;21:1637-50. [PMID: 32543284 DOI: 10.1080/14656566.2020.1774553] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
131 Loomba R, Morgan E, Watts L, Xia S, Hannan LA, Geary RS, Baker BF, Bhanot S. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 2020;5:829-38. [PMID: 32553151 DOI: 10.1016/S2468-1253(20)30186-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
132 Ross TT, Crowley C, Kelly KL, Rinaldi A, Beebe DA, Lech MP, Martinez RV, Carvajal-Gonzalez S, Boucher M, Hirenallur-Shanthappa D, Morin J, Opsahl AC, Vargas SR, Bence KK, Pfefferkorn JA, Esler WP. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems. Cell Mol Gastroenterol Hepatol 2020;10:829-51. [PMID: 32526482 DOI: 10.1016/j.jcmgh.2020.06.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
133 Boland ML, Laker RC, Mather K, Nawrocki A, Oldham S, Boland BB, Lewis H, Conway J, Naylor J, Guionaud S, Feigh M, Veidal SS, Lantier L, McGuinness OP, Grimsby J, Rondinone CM, Jermutus L, Larsen MR, Trevaskis JL, Rhodes CJ. Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab 2020;2:413-31. [PMID: 32478287 DOI: 10.1038/s42255-020-0209-6] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 21.7] [Reference Citation Analysis]
134 Neuschwander-Tetri BA. Therapeutic Landscape for NAFLD in 2020. Gastroenterology 2020;158:1984-1998.e3. [PMID: 32061596 DOI: 10.1053/j.gastro.2020.01.051] [Cited by in Crossref: 87] [Cited by in F6Publishing: 83] [Article Influence: 29.0] [Reference Citation Analysis]
135 Roumans KHM, Lindeboom L, Veeraiah P, Remie CME, Phielix E, Havekes B, Bruls YMH, Brouwers MCGJ, Ståhlman M, Alssema M, Peters HPF, de Mutsert R, Staels B, Taskinen MR, Borén J, Schrauwen P, Schrauwen-Hinderling VB. Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance. Nat Commun 2020;11:1891. [PMID: 32312974 DOI: 10.1038/s41467-020-15684-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
136 Altamirano J, Qi Q, Choudhry S, Abdallah M, Singal AK, Humar A, Bataller R, Borhani AA, Duarte-Rojo A. Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease. Transl Gastroenterol Hepatol. 2020;5:31. [PMID: 32258535 DOI: 10.21037/tgh.2019.11.14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
137 Sumida Y, Yoneda M, Ogawa Y, Yoneda M, Okanoue T, Nakajima A. Current and new pharmacotherapy options for non-alcoholic steatohepatitis. Expert Opin Pharmacother 2020;21:953-67. [PMID: 32237916 DOI: 10.1080/14656566.2020.1744564] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
138 Swiatek W, Parnell KM, Nickols GA, Scharschmidt BF, Rutter J. Validation of PAS Kinase, a Regulator of Hepatic Fatty Acid and Triglyceride Synthesis, as a Therapeutic Target for Nonalcoholic Steatohepatitis. Hepatol Commun 2020;4:696-707. [PMID: 32363320 DOI: 10.1002/hep4.1498] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
139 Wallace M, Metallo CM. Tracing insights into de novo lipogenesis in liver and adipose tissues. Semin Cell Dev Biol 2020;108:65-71. [PMID: 32201132 DOI: 10.1016/j.semcdb.2020.02.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
140 Fellinger P, Wolf P, Pfleger L, Krumpolec P, Krssak M, Klavins K, Wolfsberger S, Micko A, Carey P, Gürtl B, Vila G, Raber W, Fürnsinn C, Scherer T, Trattnig S, Kautzky-Willer A, Krebs M, Winhofer Y. Increased ATP synthesis might counteract hepatic lipid accumulation in acromegaly. JCI Insight 2020;5:134638. [PMID: 32106111 DOI: 10.1172/jci.insight.134638] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
141 Chen H. Nutrient mTORC1 signaling contributes to hepatic lipid metabolism in the pathogenesis of non-alcoholic fatty liver disease. Liver Research 2020;4:15-22. [DOI: 10.1016/j.livres.2020.02.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
142 Gao YS, Qian MY, Wei QQ, Duan XB, Wang SL, Hu HY, Liu J, Pan CY, Zhang SQ, Qi LW, Zhou JP, Zhang HB, Wang LR. WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice. Acta Pharmacol Sin 2020;41:336-47. [PMID: 31645659 DOI: 10.1038/s41401-019-0310-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
143 Esteban JPG, Asgharpour A. Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis. Gastroenterol Clin North Am 2020;49:105-21. [PMID: 32033758 DOI: 10.1016/j.gtc.2019.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
144 Cai J, Zhang XJ, Ji YX, Zhang P, She ZG, Li H. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. Circ Res 2020;126:679-704. [PMID: 32105577 DOI: 10.1161/CIRCRESAHA.119.316337] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 24.3] [Reference Citation Analysis]
145 Horn P, Newsome PN. Emerging therapeutic targets for NASH: key innovations at the preclinical level. Expert Opin Ther Targets 2020;24:175-86. [PMID: 32053033 DOI: 10.1080/14728222.2020.1728742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
146 Wu X, Huang T. Recent development in acetyl-CoA carboxylase inhibitors and their potential as novel drugs. Future Med Chem 2020;12:533-61. [PMID: 32048880 DOI: 10.4155/fmc-2019-0312] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
147 Rotman Y, Kapuria D. Non‐alcoholic Fatty Liver Disease. The Liver 2020. [DOI: 10.1002/9781119436812.ch52] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
148 Romero FA, Jones CT, Xu Y, Fenaux M, Halcomb RL. The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. J Med Chem 2020;63:5031-73. [PMID: 31930920 DOI: 10.1021/acs.jmedchem.9b01701] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 14.7] [Reference Citation Analysis]
149 Matsumoto M, Yashiro H, Ogino H, Aoyama K, Nambu T, Nakamura S, Nishida M, Wang X, Erion DM, Kaneko M. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis. PLoS One 2020;15:e0228212. [PMID: 31990961 DOI: 10.1371/journal.pone.0228212] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
150 Stern C, Ratziu V. Pharmacological Options for NASH. Non-Alcoholic Fatty Liver Disease 2020. [DOI: 10.1007/978-3-319-95828-6_17] [Reference Citation Analysis]
151 Lu Y, Su X, Zhao M, Zhang Q, Liu C, Lai Q, Wu S, Fang A, Yang J, Chen X, Yao Y. Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH. PeerJ 2019;7:e8115. [PMID: 31879571 DOI: 10.7717/peerj.8115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
152 Qureshi K, Neuschwander-Tetri BA. The molecular basis for current targets of NASH therapies. Expert Opin Investig Drugs 2020;29:151-61. [PMID: 31847612 DOI: 10.1080/13543784.2020.1703949] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
153 Takada I, Makishima M. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).Expert Opin Ther Pat. 2020;30:1-13. [PMID: 31825687 DOI: 10.1080/13543776.2020.1703952] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 11.5] [Reference Citation Analysis]
154 Noureddin M, Muthiah MD, Sanyal AJ. Drug discovery and treatment paradigms in nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00105. [PMID: 33102791 DOI: 10.1002/edm2.105] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
155 Hua W, Ten Dijke P, Kostidis S, Giera M, Hornsveld M. TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer. Cell Mol Life Sci 2020;77:2103-23. [PMID: 31822964 DOI: 10.1007/s00018-019-03398-6] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 18.5] [Reference Citation Analysis]
156 Reimer KC, Wree A, Roderburg C, Tacke F. New drugs for NAFLD: lessons from basic models to the clinic. Hepatol Int 2020;14:8-23. [PMID: 31802390 DOI: 10.1007/s12072-019-10001-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
157 Ahadi S, Gharekhani A, Shiva A. Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article. Arab Journal of Gastroenterology 2019;20:189-97. [DOI: 10.1016/j.ajg.2019.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
158 Ganguli S, DeLeeuw P, Satapathy SK. A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis. Hepat Med 2019;11:159-78. [PMID: 31814783 DOI: 10.2147/HMER.S188991] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
159 Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394:2012-2024. [PMID: 31727409 DOI: 10.1016/s0140-6736(19)32517-6] [Cited by in Crossref: 226] [Cited by in F6Publishing: 235] [Article Influence: 56.5] [Reference Citation Analysis]
160 Gapp B, Jourdain M, Bringer P, Kueng B, Weber D, Osmont A, Zurbruegg S, Knehr J, Falchetto R, Roma G, Dietrich W, Valdez R, Beckmann N, Nigsch F, Sanyal AJ, Ksiazek I. Farnesoid X Receptor Agonism, Acetyl-Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model. Hepatol Commun 2020;4:109-25. [PMID: 31909359 DOI: 10.1002/hep4.1443] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
161 Pennisi G, Celsa C, Spatola F, Dallio M, Federico A, Petta S. Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. Int J Environ Res Public Health 2019;16:E4334. [PMID: 31703268 DOI: 10.3390/ijerph16224334] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
162 Ajmera VH, Cachay E, Ramers C, Vodkin I, Bassirian S, Singh S, Mangla N, Bettencourt R, Aldous JL, Park D, Lee D, Blanchard J, Mamidipalli A, Boehringer A, Aslam S, Leinhard OD, Richards L, Sirlin C, Loomba R. MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial). Hepatology 2019;70:1531-45. [PMID: 31013363 DOI: 10.1002/hep.30674] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
163 Nelson Hayes C, Zhang P, Chayama K; Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan, Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan, Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan. The Role of Lipids in Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 95-110. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
164 Chen Z, Yu Y, Cai J, Li H. Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease. Trends Endocrinol Metab. 2019;30:903-914. [PMID: 31597607 DOI: 10.1016/j.tem.2019.08.006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 51] [Article Influence: 8.0] [Reference Citation Analysis]
165 Lemoinne S, Friedman SL. New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases. Curr Opin Pharmacol 2019;49:60-70. [PMID: 31590120 DOI: 10.1016/j.coph.2019.09.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 9.8] [Reference Citation Analysis]
166 Hodson L, Gunn PJ. The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state. Nat Rev Endocrinol 2019;15:689-700. [DOI: 10.1038/s41574-019-0256-9] [Cited by in Crossref: 89] [Cited by in F6Publishing: 90] [Article Influence: 22.3] [Reference Citation Analysis]
167 Alkhouri N, Lawitz E, Noureddin M, DeFronzo R, Shulman GI. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). Expert Opin Investig Drugs 2020;29:135-41. [PMID: 31519114 DOI: 10.1080/13543784.2020.1668374] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 13.3] [Reference Citation Analysis]
168 Wong VW, Singal AK. Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis. Transl Gastroenterol Hepatol. 2019;4:53. [PMID: 31463412 DOI: 10.21037/tgh.2019.06.06] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
169 Manka P, Zeller A, Syn W. Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. Drugs 2019;79:903-27. [DOI: 10.1007/s40265-019-01126-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
170 Esler WP, Bence KK. Metabolic Targets in Nonalcoholic Fatty Liver Disease. Cell Mol Gastroenterol Hepatol 2019;8:247-67. [PMID: 31004828 DOI: 10.1016/j.jcmgh.2019.04.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 17.3] [Reference Citation Analysis]
171 Naini A, Sasse F, Brönstrup M. The intriguing chemistry and biology of soraphens. Nat Prod Rep 2019;36:1394-411. [PMID: 30950477 DOI: 10.1039/c9np00008a] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
172 Gu J, Liu S, Du S, Zhang Q, Xiao J, Dong Q, Xin Y. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol 2019;29:3564-73. [DOI: 10.1007/s00330-019-06072-4] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 19.8] [Reference Citation Analysis]
173 Yu Y, Cai J, She Z, Li H. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. Adv Sci (Weinh) 2019;6:1801585. [PMID: 30828530 DOI: 10.1002/advs.201801585] [Cited by in Crossref: 60] [Cited by in F6Publishing: 72] [Article Influence: 15.0] [Reference Citation Analysis]
174 Adams LA. End-points for drug treatment in NASH. Hepatol Int 2019;13:253-8. [DOI: 10.1007/s12072-019-09935-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
175 Orlicky DJ, Libby AE, Bales ES, McMahan RH, Monks J, La Rosa FG, McManaman JL. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions. J Physiol 2019;597:1565-84. [PMID: 30536914 DOI: 10.1113/JP277140] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 8.5] [Reference Citation Analysis]
176 Wong VWS, Adams LA. Fibroblast growth factor 21 for non-alcoholic steatohepatitis. Lancet 2019;392:2658-60. [PMID: 30554786 DOI: 10.1016/S0140-6736(18)32165-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
177 Goedeke L, Bates J, Vatner DF, Perry RJ, Wang T, Ramirez R, Li L, Ellis MW, Zhang D, Wong KE, Beysen C, Cline GW, Ray AS, Shulman GI. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents. Hepatology 2018;68:2197-211. [PMID: 29790582 DOI: 10.1002/hep.30097] [Cited by in Crossref: 132] [Cited by in F6Publishing: 128] [Article Influence: 26.4] [Reference Citation Analysis]
178 Sayiner M, Lam B, Golabi P, Younossi ZM. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2018;11:1756284818811508. [PMID: 30479664 DOI: 10.1177/1756284818811508] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
179 Nakagawa H, Hayata Y, Kawamura S, Yamada T, Fujiwara N, Koike K. Lipid Metabolic Reprogramming in Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E447. [PMID: 30445800 DOI: 10.3390/cancers10110447] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 14.2] [Reference Citation Analysis]
180 Mehal WZ. Acetyl-Coenzyme A carboxylase inhibition Delivers, as Anticipated, for Patients With Nonalcoholic Steatohepatitis. Gastroenterology 2018;155:1304-6. [PMID: 30308191 DOI: 10.1053/j.gastro.2018.10.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]